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The emergence of mutations that confer resistance
to molecularly targeted therapeutics is dependent
upon the effect of each mutation on drug affinity for
the target protein, the clonal fitness of cells harboring
the mutation, and the probability that each variant
can be generated by DNA codon base mutation.
We present a computational workflow that combines
these three factors to identifymutations likely to arise
upon drug treatment in a particular tumor type. The
Osprey-based workflow is validated using a compre-
hensive dataset of ERK2 mutations and is applied to
small-molecule drugs and/or therapeutic antibodies
targeting KIT, EGFR, Abl, and ALK. We identify
major clinically observed drug-resistant mutations
for drug-target pairs and highlight the potential
to prospectively identify probable drug resistance
mutations.
INTRODUCTION
Although targeted cancer therapies, for example, against ki-
nases, hormone receptors, or hormone-synthesizing enzymes,
have shown clinical success, many patients develop resistance
to treatment and subsequently relapse. Second- and third-gen-
eration drugs are being developed to target these resistant
mutants; however, there is a significant time span between the
detection of clinically validated resistance mutations and the
availability of suitably targeted treatment options. Early identifi-
cation of drug-specific mutations is therefore critical and the
aim of this study.
Several mechanisms underlying resistance to targeted drugs
have been described (Holohan et al., 2013), including mutations
directly affecting the drug target. Such mutations may, for
example, increase affinity for the endogenous co-factor ATP,
thereby decreasing the relative affinity of an ATP-competitive
drug. Mutations within the binding site may also alter drug-
protein interactions and directly interfere with drug binding
(Barouch-Bentov and Sauer, 2011).
Several computational studies have investigated the impact of
protein mutations on drug efficacy (Kamasani et al., 2017; Mar-Cell Chemical Biology 25, 1–13, Nov
This is an open access article undtı´nez-Jime´nez et al., 2017; Paul et al., 2016; Reeve et al.,
2015), mainly in an antiviral or antibacterial context (Frey et al.,
2010; Hosseini et al., 2016; Fowler et al., 2018). However, rarely
do these studies prospectively identify drug resistance muta-
tions (Frey et al., 2010; Paul et al., 2016; Reeve et al., 2015). In
predicting mutations that render Staphylococcus aureus resis-
tant to an antifolate antibiotic, Reeve et al. (2015) evaluated the
likely effect of possible mutations on both binding of the inhibitor
and on binding of the endogenous ligand— an important aspect
since any mutation that significantly abrogates the native activity
of the wild-type (WT) protein is unlikely to survive selective evolu-
tionary pressure (Gil and Rodriguez, 2016; Sprouffske et al.,
2012; Pandurangan et al., 2017). However, Reeve et al. do not
consider the likelihood of whether each mutation can be formed
in bacteria.
In cancer, the mutation landscape of a tumor can be charac-
terized by themutational signatures operating in a particular can-
cer type (Alexandrov et al., 2013). These signatures describe the
probability of a specific base exchange within a defined trinucle-
otide context. Some of these signatures have been associated
with known mutagenic processes, such as UV irradiation or ag-
ing, while the mechanism of others still remains elusive (Alexan-
drov et al., 2013). These mutagenic processes can generate a
single clone harboring the disease-causing ‘‘driver mutation,’’
which ultimately leads to the development of cancer (Greaves
and Maley, 2012). In addition, non-transforming somatic muta-
tions, so-called passenger mutations, are randomly created.
While not oncogenic per se, passenger mutations can provide
the substrate for an evolutionary advantage throughout cancer
progression, for example, under the selective pressure of a tar-
geted molecular therapy, leading to drug resistance. Known
drug resistance mutations have not only been detected in treat-
ment-naive patients (Inukai et al., 2006; Roche-Lestienne et al.,
2002), but also in healthy individuals (Gurden et al., 2015). This
suggests that small pools of viable treatment-resistant clones
can pre-exist in patients and that drug treatment puts a selection
pressure on a heterogeneous cancer cell population that selects
for resistant sub-clones.
Each drug interacts with its biological target in a unique way,
and each protein target mutation will differentially affect diverse
classes of drugs. As a consequence, each compound can be ex-
pected to exhibit a unique resistancemutation profile. Three fac-
tors contribute to the probability and functional impact of a res-
idue change: (1) the probability that the protein mutation can be
generated from a DNA mutational signature (signature-drivenember 15, 2018 ª 2018 The Author(s). Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Workflow
Potential mutations are evaluated based on their predicted effect on the affinity
of both the drug and endogenous ligand (orange), the fitness of the resultant
clone (blue), and the requirement for triple-point mutations to generate a
mutant (lime green). Resistance hotspots are identifiedwithin the remaining set
of resistant mutants; these resistance hotspots are protein residues where
multiple amino acid changes are predicted to lead to resistance and which
therefore have a high likelihood of functional relevance. Resistant mutations at
these hotspots are prioritized based on the probability that they will be
generated according to the known DNA mutational signatures operating in a
particular cancer type.
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Resistance Mutations in Cancer, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.013probability), (2) whether the mutation maintains protein function
and clones harboring the mutation are still viable (fitness), and
(3) whether the mutation confers lower drug affinity with respect
to the endogenous ligand for the target protein (affinity). Martı´-
nez-Jime´nez et al. (2017) recently reported a workflow classi-2 Cell Chemical Biology 25, 1–13, November 15, 2018fying potential drug resistance mutations based on Random
Forest models and mutation signatures. However, the effect of
mutations on the fitness of the clone was not taken into account.
In addition, only single-point mutations (SPMs) were considered,
despite the notable detection of double-point mutations (DPMs)
in cancer patients (Table S1).
We report an in silico cascade that sequentially evaluates the
probability of generating anymutant within 5 A˚ of a bound ligand,
the clonal fitness of each mutation, and the effect of each muta-
tion on drug affinity in order to systematically and objectively
prioritize mutations that are highly likely to arise under drug
treatment. Importantly, our workflow classifies the impact of a
mutation on drug affinity relative to endogenous ligand and
does not rely upon accurate calculation of binding free energies;
it also ranks mutations according to their likelihood of being
generated in particular cancer type. The workflow (Figure 1
and described in detail below) is validated on a comprehensive
benchmark dataset that describes the effect of nearly all
possible extracellular signal-regulated kinase 2 (ERK2) missense
mutations on sensitivity to the ERK2 inhibitor SCH772984
(Brenan et al., 2016). In addition, we apply the workflow to four
well-established cancer targets and evaluate at least two US
Food and Drug Administration-approved drugs (small molecules
or biologics) per target.
RESULTS
Affinity
In the first step, the software package Osprey (Chen et al., 2009;
Gainza et al., 2013) was applied to evaluate the potential impact
of protein active site mutations on both drug and endogenous
ligand binding using protein crystallographic data.
Osprey uses ensembles of minimized side chain rotamers to
calculate a K* score (Chen et al., 2009; Gainza et al., 2013), which
estimates ligand binding to the evaluated protein construct.
Importantly, by employing ensembles of rotamers, Osprey
takes the dynamic nature of protein amino acid side chains
into account.
K* scores were computed for the WT protein and all possible
amino acid exchanges for both the drug and the endogenous
ligand-protein complex with the exception of Pro, which cannot
be processed byOsprey.We identify mutants that reduce affinity
for the drug in comparison with the endogenous ligand and are
therefore more likely to drive a viable resistant clone. Impor-
tantly, calculation of absolute drug affinity for WT and mutant
proteins is not required. Please refer to the STAR Methods for
additional details.
Fitness
Clones harboring a mutant oncoprotein that is unable to bind its
endogenous ligand lose their function and are unlikely to persist.
All such deleterious mutants with a K* score of 0.0 for the endog-
enous ligand were discarded.
Exclusion of Triple Point Mutations
Base codons for each WT residue were retrieved from the
COSMIC database (Bamford et al., 2004). Amino acid ex-
changes that would require mutation of all three codon bases
were discarded. We hypothesized that three contiguous coding
Please cite this article in press as: Kaserer and Blagg, Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific
Resistance Mutations in Cancer, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.013base mutations are highly unlikely and, to the best of our knowl-
edge, no such patient case has been reported.While themajority
of drug resistance mutations arise from SPMs, we also included
DPMs (so-called tandem mutations), which represent 5% (7 of
132) of unique drug resistance mutations with defined genetic
alterations in the COSMIC database (access date 5 January
2018) and occur with similar frequency to insertions (Table S1).
Resistance Hotspots and Signature-Driven Probability
Functional protein mutants were further triaged according to the
number of predicted mutations at a specific residue position.
This approach identifies resistance hotspots, where multiple
different viable mutants are predicted to cause resistance to
the drug under study. While comparing the prevalence of muta-
tions at hotspots in a particular drug-target pair can be used for
ranking positions, this method cannot be applied to cross-
compare the prevalence of mutations at hotspots between
drug-target pairs to infer global inter-target susceptibility to
resistance. The top three ranked resistance hotspots were
then analyzed in more detail in order to further prioritize amino
acid changes at these positions that have a high probability
(relP) of being generated in particular tumor types according to
the DNA mutational signatures reported by Alexandrov et al.
(2013). Each possible resistance hotspot mutation was ranked
according to its derived relP and the top-ranked amino acid
changes were considered most relevant. Please refer to the
STAR Methods for additional details.
ERK2: A Benchmarking Study
In 2016, Brenan and colleagues systematically studied the
effect of a wide range of ERK2 genetic alterations on the cellular
response to the ERK2 inhibitor SCH772984 (Brenan et al., 2016).
They generated nearly every possible missense mutation using
multiplexed site-directed mutagenesis. Pooled vectors were
used to express ERK2 mutants in A375 human malignant mela-
noma cells; after drug exposure, the enrichment of resistant
variants relative to their abundance in the initial cell population
was determined by massively parallel sequencing.
This comprehensive dataset of possible resistant mutants to
the ERK2 inhibitor SCH772984 provides a benchmark to eval-
uate the performance of our workflow. However, as a conse-
quence of the aggressive mutant-generation protocol, this data-
set includes protein mutants that require exchange of all three
coding bases. Such mutants are excluded in our workflow (see
above) and were also removed from the Brenan dataset.
Brenan and colleagues reported 46 experimentally observed
resistance mutations within 5 A˚ of the bound ligand that were
not mutations to Pro or triple-point mutations. For SCH772984,
559 mutants covering 31 residues were evaluated by our work-
flow. The number of true-positive (TP) (mutants predicted to
confer resistance that were confirmed by experimental testing),
true-negative (mutants predicted to be sensitive that did not
confer resistance in experimental testing), false-positive (FP)
(mutants predicted to confer resistance that were found to be
sensitive in experimental testing), and false-negative (mutants
predicted to be sensitive, but conferred resistance in the exper-
imental testing) predictions was calculated (Figure 2A).
Our workflow correctly classifies 84.6% of mutants and iden-
tifies almost 40% of the experimentally observed resistance mu-tations reported by Brenan et al. When considering only residue
positions, 80% of experimentally observed mutated residues
are discovered. The majority of experimentally evaluated ERK2
mutants remained sensitive to SCH772984 treatment and are
correctly identified as sensitive by our approach, contributing
to the high overall proportion (84.6%) of correct predictions.
The low TP rate for SCH772984 (3.2% of mutants predicted to
confer resistance were confirmed by experimental testing) is
consistent with the experimental observation that only a small
proportion of possible mutants (8.2%) cause drug resistance.
The prioritized hotspot residues and their corresponding re-
ported resistance mutations are provided in Table 1. For a
detailed list of all predicted mutations please refer to Table S2.
Clinical Case Studies
We studied four protein kinases (KIT, epidermal growth factor
receptor [EGFR], breakpoint cluster region-Abelson [Bcr-Abl]
kinase, and anaplastic lymphoma kinase [ALK]). In each case
protein-ligand crystal structures of approved drugs exemplify
multiple generations of compound design; furthermore, as inhib-
itors of these targets provide the current standard of care for
multiple cancer types, clinically observed resistance mutations
are documented for most compounds and provide the potential
for clinical validation of our computational workflow.
KIT
The first-generation inhibitor imatinib is resistant to the KIT gate-
keeper mutation T670I (Antonescu et al., 2005; Tamborini et al.,
2004). We investigated 648 possible mutations, all of which lie
within 5 A˚ of either imatinib or ADP; 68 mutations remained after
filtering for reduced drug binding, fitness of the clones, and tri-
ple-point mutants. For residue T670, eight mutations are pre-
dicted to cause resistance to imatinib, making it the first-ranked
resistance hotspot; within this set, gatekeeper mutation T670I
has the highest relP. Furthermore, the known resistance muta-
tion T670E (Wardelmann et al., 2005) is ranked sixth by relP.
Positions C809 and V668 are identified as second- and third-
ranked resistance hotspots, respectively. C809R, the mutation
with the highest relP, has been reported in a patient diagnosed
with myelodysplastic syndrome-derived leukemia (Lorenzo
et al., 2006), highlighting its biological relevance; however,
similar to all predicted V668 mutations, this residue has not yet
been associated with imatinib resistance.
The second-generation inhibitor sunitinib is reported to over-
come resistance to the gatekeeper mutation T670I and, consis-
tent with these reports, T670I/E mutations are not predicted to
elicit sunitinib resistance by our workflow. Indeed, none of our
predicted resistance mutations to sunitinib has yet been associ-
atedwith clinically observed resistance. Only one resistancemu-
tation has so far been reported for sunitinib in the COSMIC data-
base (Bamford et al., 2004, access date 23 November 2017); this
mutation is not within the ATP-binding site.
Ponatinib has been shown to bind KIT, but is not approved
for KIT-associated cancer types and clinical data are therefore
lacking. Our method predicts resistance to ponatinib due to
less-favorable interactions with the gatekeeper T607I mutation;
however, in vitro data suggest that this mutant is sensitive to po-
natinib treatment (Garner et al., 2014). Prioritized KIT resistance
hotspot residues and their corresponding reported clinicalCell Chemical Biology 25, 1–13, November 15, 2018 3
Figure 2. Predicted Resistance Mutations
(A) Performance of the workflow on ERK2-SCH772984. The confusion matrix shows the absolute number of mutations (+, resistant; , sensitive).
(B) Predicted resistance hotspots that are consistent with clinically observed resistant mutants for the representative case study EGFR (gray) and osimertinib
(orange), PDB: 4ZAU (Yosaatmadja et al., 2015). Residues within 5 A˚ of the ligand are depicted in gray, predicted and clinically observed resistance hotspots are
highlighted as crimson sticks and labeled, predicted hotspot residues that have not yet been observed in the clinic are shown as pink sticks; figure created with
PyMOL (PyMOL Molecular Graphics System, Version 1.7, Schro¨dinger, LLC).
(C) Contribution of filtering steps to the identification of resistancemutations. Themajority of mutants were discarded because they did not decrease drug affinity
in comparison with binding of the endogenous ligand (orange). Mutations were further removed because of abrogated clonal fitness (blue) or because they
required triple codon changes to be formed (green). The remaining pool of mutations (crimson) is predicted likely to confer resistance to drug treatment.
Please cite this article in press as: Kaserer and Blagg, Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific
Resistance Mutations in Cancer, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.013resistance mutations are provided in Table 2. A full list of pre-
dicted resistance mutations and their relP values is available in
Table S3.
EGFR
Applying our workflow to the first-generation EGFR inhibitor
erlotinib revealed that G796 is the resistance hotspot with the4 Cell Chemical Biology 25, 1–13, November 15, 2018most predicted mutations. Consistent with this prediction, the
G796Rmutation with the second-ranked relP, has been reported
to weaken the affinity for erlotinib in comparison with the WT
enzyme (Avizienyte et al., 2008). T790 is the second-ranked
resistance hotspot with gatekeeper mutation T790M (Pao
et al., 2005) having the second highest relP. L718, L788, and
T854 share the third-ranked hotspot, with three predicted
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Resistance Mutations in Cancer, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.013mutations each. L788F has been detected in lung adenocarci-
noma patient samples highlighting its clinical relevance (Liu
et al., 2013); however, similar to all other third-rank mutations,
L788F has not yet been associated with clinical resistance to er-
lotinib. Gefitinib, another first-generation EGFR inhibitor, elicits a
similar predicted resistant mutation profile to erlotinib (Table 3).
The third-generation inhibitor osimertinib binds reversibly to
EGFR prior to covalent bond formation (Yosaatmadja et al.,
2015). Osimertinib was reported to overcome resistance to
T790M and, consistent with this finding, the T790M mutation is
not predicted to elicit resistance to osimertinib according to
our protocol. Residues G796 (14 mutations), C797 (4 mutations),
L718, G719, V726, and A743 (3 mutations each) are the top-
ranked hotspot residues predicted to confer resistance. During
the preparation of this manuscript, osimertinib resistance muta-
tions affecting C797 (Ou et al., 2017b), G796 (Ou et al., 2017b;
Zheng et al., 2017), and L718 (Ou et al., 2017a) (Figure 2B)
were reported in clinical studies, building confidence in the pro-
spective utility of our approach.
Further to small-molecule EGFR inhibitors, anti-EGFR mono-
clonal antibodies cetuximab and panitumumab are approved
for the treatment of metastatic colorectal cancer. In contrast to
small-molecule ATP-competitive kinase inhibitors, cetuximab
and panitumumab interact with the extracellular domain
of EGFR.
We evaluated the effect of extracellular domain mutations on
antibody affinity and affinity of the endogenous ligands EGF
and transforming growth factor a (TGF-a)––interactions that
have been characterized by protein structural data. Both EGF
and TGF-a are peptidic macromolecules with larger interaction
surfaces compared with small molecules; thus evaluation of a
higher number of possible mutations was necessary to ensure
coverage of the extensive protein-protein interaction interface
(1,153 and 1,207 mutations for cetuximab and panitumumab,
respectively).
For both cetuximab and panitumumab, resistance mutation
G441R (residue G465R in the mature protein sequence including
the signaling peptide [mps]) has been detected in the clinic (Braig
et al., 2015). G441 is the second-ranked resistance hotspot, with
mutation G441R ranked first according to relP for both anti-
bodies (Table 3). Confirmed clinical resistance mutations to
cetuximab have also been identified at residues S468 (S468R
[S492R in the mps]) (Montagut et al., 2012) and I467 (Arena
et al., 2015) (I467M [I491M in the mps]); the fourth- and fifth-
ranked resistance hotspots in our workflow (Table S4).
Our top-ranked predicted hotspot residues, S418 and G471
have not yet been associated with clinical resistance to cetuxi-
mab or panitumumab; however, seven endogenous ligands
can activate EGFR (Schneider and Wolf, 2009) of which only
EGF and TGF-a interactions are characterized by protein struc-
tural data. Residues S418 and G471, while not predicted to
affect the interaction of EGFR with endogenous ligands EGF
and TGF-a, may be important for interaction with one or more
of the remaining five endogenous ligands such that mutation at
these residues reduces clonal fitness and persistence. For
example, we predict that several mutations affecting EGFR res-
idues S440 and V417 tolerate TGF-a binding, but abrogate EGF
binding, and are therefore filtered out in our workflow. Given the
lack of structural data for the majority of endogenous EGFRCell Chemical Biology 25, 1–13, November 15, 2018 5
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of clinically relevant resistance mutations is encouraging. All
prioritized EGFR hotspot residues and corresponding reported
clinical resistance mutations are summarized in Table 3. A list
of all predicted mutations and relPs is provided in Table S4.
Abl
The hotspot residue with the highest number of predicted mu-
tants for the Abl inhibitor imatinib is A380, for which clinically
observed occurrences have yet to be reported. The second-
rank predicted hotspot is shared by residues V256, A269, and
T315. For V256 and T315, resistance mutations V256L (Bamford
et al., 2004; Tiribelli et al., 2013), gatekeeper mutation T315I
(Gorre et al., 2001), and T315V (Redaelli et al., 2012) have all
been identified in the clinic (Table 4). The contribution of muta-
tional signatures to the landscape of mutations has not yet
been reported for chronicmyeloid leukemia (CML), and therefore
the relP for hotspot mutations predicted for Abl residues could
not be calculated.
We obtained similar and consistent predictions for nilotinib,
dasatinib, and bosutinib (Table 4). Additional resistance muta-
tions affecting L248 are predicted for dasatinib consistent with
in vitro data (Redaelli et al., 2012). While these mutations have
been observed in the clinic (Redaelli et al., 2012), they have not
yet been reported as resistant mutants for patients treated with
dasatinib. Similarly, the effect of the predicted V256L resistant
mutation on nilotinib activity has not been reported.
Axitinib has been reported to overcome resistance to the T315I
gatekeeper mutation of Abl (Pemovska et al., 2015). Although not
ranked among the top three resistance hotspots, axitinib is pre-
dicted to be resistant to T315I. Crystallographic studies of the
T315Imutation incomplexwithaxitinib revealed that thismutation
causes large conformational changes of Abl compared with WT
protein (Pemovska et al., 2015), which may not be adequately
captured by our method. The L248Rmutation, reported to confer
resistance to axatinib in vitro (Pemovska et al., 2015), is prioritized
by our workflow; however, clinical resistance data for axitinib tar-
getingAbl is notyetavailable.A summaryof theprioritizedAblhot-
spot residuesand their corresponding reportedclinical resistance
mutationsareprovided inTable4.A full list of predicted resistance
mutations is provided in Table S5.
ALK
The hotspot residue with the highest frequency of predicted
mutations for the first-generation ALK inhibitor crizotinib is
G1269 (13 mutants). The clinically observed resistance mutation
G1269A (Doebele et al., 2012; Gainor et al., 2016) and G1269S
and G1269C mutations (Zhang et al., 2011), which confer resis-
tance in vitro, rank at positions four, seven, and eight, respec-
tively, based upon their relP values. For the second-ranked resis-
tance hotspot G1202, 12mutants were predicted and the known
resistance mutation G1202R (Gainor et al., 2016; Katayama
et al., 2012) has the second highest relP. Hotspots I1122,
G1201, and D1203 rank third equal. While no G1201 mutations
are associated with resistance, the D1203N mutation confers
resistance in vitro (Gainor et al., 2016; Heuckmann et al., 2011)
and has been associated with resistance in patients (Zhang
et al., 2016). I1122V has been detected in a resistance screen
against the second-generation inhibitor brigatinib, and has also
T
a
b
le
3
.
P
ri
o
ri
ti
z
e
d
E
G
F
R
R
e
s
is
ta
n
c
e
M
u
ta
ti
o
n
s
C
o
m
p
o
u
n
d
N
o
.
o
f
P
re
d
M
u
t
(N
o
.
o
f
A
ll
M
u
t)
a
R
a
n
k
1
R
e
s
is
ta
n
c
e
H
o
ts
p
o
t
(N
o
.
o
f
M
u
t)
b
C
o
n
fi
rm
e
d
C
lin
ic
a
l
R
e
s
is
ta
n
c
e
M
u
ta
n
ts
(R
a
n
k
re
lP
)c
R
a
n
k
2
R
e
s
is
ta
n
c
e
H
o
ts
p
o
t
(N
o
.
o
f
M
u
t)
b
C
o
n
fi
rm
e
d
C
lin
ic
a
l
R
e
s
is
ta
n
c
e
M
u
ta
n
ts
(R
a
n
k
re
lP
)
R
a
n
k
3
R
e
s
is
ta
n
c
e
H
o
ts
p
o
t
(N
o
.
o
f
M
u
t)
b
C
o
n
fi
rm
e
d
C
lin
ic
a
l
R
e
s
is
ta
n
c
e
M
u
ta
n
ts
(R
a
n
k
re
lP
)
E
rl
o
ti
n
ib
3
4
(4
6
9
)
G
7
9
6
(9
)
N
R
d
T
7
9
0
(5
)
T
7
9
0
M
(2
)
(P
a
o
e
t
a
l.,
2
0
0
5
)
L
7
1
8
(3
)
L
7
8
8
(3
)
T
8
5
4
(3
)
N
R
G
e
fi
ti
n
ib
4
3
(4
8
7
)
G
7
9
6
(1
4
)
G
7
9
6
A
(3
)
(U
ra
m
o
to
e
t
a
l.,
2
0
0
7
)
T
7
9
0
(6
)
T
7
9
0
M
(2
)
(K
o
b
a
y
a
s
h
i
e
t
a
l.,
2
0
0
5
;
P
a
o
e
t
a
l.,
2
0
0
5
)
T
8
5
4
(4
)
N
R
O
s
im
e
rt
in
ib
3
8
(4
1
5
)
G
7
9
6
(1
4
)
G
7
9
6
S
(1
)
(O
u
e
t
a
l.,
2
0
1
7
b
)
G
7
9
6
D
(2
)
(Z
h
e
n
g
e
t
a
l.,
2
0
1
7
)
G
7
9
6
R
(5
)
(O
u
e
t
a
l.,
2
0
1
7
b
)
C
7
9
7
(4
)
C
7
9
7
R
(3
)
(O
u
e
t
a
l.,
2
0
1
7
b
)
L
7
1
8
(3
)
G
7
1
9
(3
)
V
7
2
6
(3
)
A
7
4
3
(3
)
N
R
C
e
tu
x
im
a
b
6
5
(1
,1
5
3
)
G
4
7
1
(1
5
)
N
R
G
4
4
1
(1
2
)
G
4
4
1
R
(1
)
(B
ra
ig
e
t
a
l.,
2
0
1
5
)
S
4
1
8
(1
0
)
N
R
P
a
n
it
u
m
u
m
a
b
6
5
(1
,2
0
7
)
S
4
1
8
(1
4
)
N
R
G
4
4
1
(1
2
)
G
4
4
1
R
(1
)
(B
ra
ig
e
t
a
l.,
2
0
1
5
)
G
4
7
1
(8
)
N
R
S
e
e
a
ls
o
T
a
b
le
S
4
.
a
T
h
e
n
u
m
b
e
r
o
f
m
u
ta
n
ts
p
re
d
ic
te
d
to
c
o
n
fe
r
re
s
is
ta
n
c
e
(n
o
.
o
f
p
re
d
m
u
t)
fr
o
m
th
e
in
it
ia
l
p
o
o
l
o
f
p
o
s
s
ib
le
m
u
ta
n
ts
w
it
h
in
5
A˚
o
f
th
e
lig
a
n
d
s
(n
o
.
o
f
a
ll
m
u
t)
.
b
R
e
s
is
ta
n
c
e
h
o
ts
p
o
ts
a
re
id
e
n
ti
fi
e
d
a
n
d
ra
n
k
e
d
a
c
c
o
rd
in
g
to
th
e
n
u
m
b
e
r
o
f
v
ia
b
le
m
u
ta
n
ts
(n
o
.
o
f
m
u
t)
p
re
d
ic
te
d
fo
r
a
re
s
id
u
e
.
c
T
h
e
re
lP
w
a
s
c
a
lc
u
la
te
d
fo
r
a
ll
re
s
is
ta
n
c
e
h
o
ts
p
o
t
m
u
ta
ti
o
n
s
.
C
lin
ic
a
lly
o
b
s
e
rv
e
d
re
s
is
ta
n
c
e
m
u
ta
ti
o
n
s
a
n
d
th
e
ir
ra
n
k
a
c
c
o
rd
in
g
to
re
lP
(r
a
n
k
re
lP
)
a
re
h
ig
h
lig
h
te
d
fo
r
e
a
c
h
re
s
is
ta
n
c
e
h
o
ts
p
o
t.
d
N
R
,
n
o
t
re
p
o
rt
e
d
–
–
n
o
n
e
o
f
th
e
p
re
d
ic
te
d
m
u
ta
ti
o
n
s
a
re
re
p
o
rt
e
d
to
c
o
n
fe
r
re
s
is
ta
n
c
e
a
g
a
in
s
t
th
e
d
ru
g
.
T
h
e
g
a
te
k
e
e
p
e
r
m
u
ta
ti
o
n
is
u
n
d
e
rl
in
e
d
.
Please cite this article in press as: Kaserer and Blagg, Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific
Resistance Mutations in Cancer, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.013been confirmed to confer resistance to crizotinib (Ceccon et al.,
2015).We generated similar results for the second-generation in-
hibitor ceritinib (Table 5), although, in this case, the G1269A mu-
tation was not predicted to cause resistance, consistent with
in vitro and clinical data (Gainor et al., 2016; Shaw et al., 2015).
Entrectinib and lorlatinib are investigational ALK inhibitors
currently in clinical trials. Increased half maximal inhibitory con-
centration values (decreased binding) in comparison with theWT
protein have been demonstrated in in vitro experiments for
several of the mutants prioritized by our workflow. In particular,
G1269A (Ardini et al., 2016) and G1202R (Ardini et al., 2016) for
entrectinib and G1269A (Gainor et al., 2016; Johnson et al.,
2014; Shaw et al., 2015) and D1203N (Gainor et al., 2016) for lor-
latinib. In addition, the G1123S and G1123D mutants were iden-
tified in an in vitro resistance screen for the ALK inhibitor TAE684
(Heuckmann et al., 2011) and in a patient resistant to ceritinib
(Toyokawa et al., 2015). However, no data are currently available
on entrectinib. The prioritized hotspot residues for ALK and cor-
responding reported clinical resistance mutations are provided
in Table 5. A comprehensive list of all predicted resistancemuta-
tions is provided in Table S6.
DISCUSSION
We present a computational workflow to identify clinically rele-
vant drug resistance mutations to targeted cancer therapies,
both small molecule and biological. The workflow consists of
consecutive filtering steps addressing three factors, which
determine whether a mutation is likely to confer resistance in
the clinic. Of these, the activity cutoff for protein-drug affinity
compared with affinity for the endogenous ligand proved the
most important and excluded 75.8% ± 1.1% (n = 18 [all
18 target-interaction partner case studies] ±SEM) of all potential
mutants for each drug-target combination (Figure 2C). This
filtering step contains a fitness component; all mutants with pre-
dicted decreased affinity for the endogenous ligand (i.e., less fit
clones), but with equivalent or increased affinity for the drug (i.e.,
more sensitive to drug treatment) are not progressed. In further
considering the potential for disrupted binding of an endogenous
ligand to mutated proteins, 8.6% ± 0.7% (n = 18, ±SEM) of
mutants are predicted to completely abrogate binding of the
endogenous ligand and were discarded. Removing triple-point
mutations excluded a further 3.7% ± 0.2% (n = 18, ±SEM)
of possible mutants. Interestingly, the majority of remaining
mutations predicted to cause resistance (68.1% ± 1.7%
[n = 18, ±SEM]) arise from DPM consistent with a similar
proportion of DPMs observed in the Brenan dataset (Brenan
et al., 2016). While DPMs commonly exhibit a low relP, they
may become relevant when the predominant resistance clone
harboring an SPM has been eradicated by cancer therapy.
Taken together, 11.8% ± 1.0% (n = 18, ±SEM) of all evaluated
mutations were considered to cause resistance (Figure 2C).
The pool of potential resistant mutations was further analyzed
to identify resistance hotspots where multiple different viable
mutants are predicted to cause resistance to the drug under
study. Mutants at these hotspots were prioritized based on their
relP, which quantifies the relative probability of each specific
amino acid mutation in the context of a defined cancer type.
Applying this workflow, we correctly classify 84.5% of mutationsCell Chemical Biology 25, 1–13, November 15, 2018 7
Table 4. Prioritized Abl Resistance Mutations
Compound
No. of Pred Mut
(No. of All Mut)a
Rank 1 Resistance
Hotspot (No. of Mut)b
Confirmed Clinical
Resistance Mutationsc
Rank 2 Resistance
Hotspot (No. of Mut)b
Confirmed Clinical
Resistance Mutations
Rank 3 Resistance
Hotspot (No. of Mut)b
Confirmed Clinical
Resistance Mutations
Imatinib 66 (540) A380 (8) NRd V256 (7)
A269 (7)
T315 (7)
V256L (Bamford et al., 2004;
Tiribelli et al., 2013)
T315I (Gorre et al., 2001)
NAe –
Nilotinib 69 (540) V256 (8)
A380 (8)
NR NA – Y253 (6)
A269 (6)
T315 (6)
G321 (6)
T315I (Bamford et al., 2004;
Redaelli et al., 2012;
Weisberg et al., 2005)
Dasatinib 58 (414) A380 (12) NR L248 (7)
A269 (7)
NR NA –
Bosutinib 58 (414) V299 (7)
T315 (7)
G321 (7)
V299L (Jabbour et al., 2012;
Redaelli et al., 2012)
T315I (Cortes et al., 2011;
Redaelli et al., 2012)
NA – NA –
Axitinib 52 (396) V256 (8) NR G321 (7) NR L248 (6)
A269 (6)
A380 (6)
NR
See also Table S5.
aThe number of mutants predicted to confer resistance (no. of pred mut) from the initial pool of possible mutants within 5 A˚ of the ligands (no. of all mut).
bResistance hotspots are identified and ranked according to the number of viable mutants (no. of mut) predicted for a residue.
cClinically observed resistance mutations are highlighted for each resistance hotspot. The relP could not be calculated as signatures for CML were not available.
dNR, not reported––none of the predicted mutations were reported to confer resistance. In the case of axitinib, clinical resistance data on Abl are not yet available.
eNA, not applicable, tied resistance hotspot at rank 1 or 2. The gatekeeper mutation is underlined.
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40% of mutants conferring resistance to the ERK2 inhibitor
SCH772984. Furthermore, we identify clinically observed drug
resistance mutations within the top three predicted hotspot res-
idues for first-generation compounds in all cases studied and for
most second- and third-generation compounds where clinically
observed resistance mutations have been reported. Importantly,
in all cases studied, except ALK, the gatekeeper mutation is pre-
dicted among the top three resistance hotspots. In the ALK case
study, two mutations that are also commonly observed in the
clinic are highly ranked by our method. For the osimertinib-
EGFR drug-target pair, we predicted resistance mutations
before they were confirmed by clinical reports.
Our workflow highlights mutations not yet observed in the
clinic, or that may constitute FP predictions. The number of mu-
tants progressed to further evaluation can be user defined. In the
cases exemplified here, we prioritize three mutations with the
highest relP for the top three resistance hotspots and signifi-
cantly narrow the pool of potential resistance mutations for
each drug from 350–1,200 possibilities to 9. While it may not
be practical to further explore many hundreds of possible muta-
tions, we suggest that a set of 9 prioritized mutants is more
amenable to experimental testing within a drug discovery project
or clinical setting. Thus, this workflow facilitates more focused
monitoring of potential resistant mutations, as well as the
design of next-generation compounds sensitive to likely resis-
tant mutants.
Notably, our workflow evaluates the effect of a mutation on
drug binding with respect to the WT protein. In some cases,
exquisite drug affinity for the WT protein may mitigate a muta-
tion-driven loss of potency. For example, our workflow correctly
predicted the reduced affinity of lorlatinib for ALK G1269A; how-
ever, the exquisite potency of lorlatinib for WT ALK may render
the relative loss of affinity for ALK mutants inconsequential
(Gainor et al., 2016; Johnson et al., 2014; Shaw et al., 2015).
The workflow is dependent upon the availability and quality of
both protein-ligand structural information and mutational signa-
tures across diverse tumor types. For example, it is not clear
which mutational signatures operate in CML, and, as a conse-
quence, we could not determine the relP for mutants predicted
to interfere with binding of Abl inhibitors in CML.
The approach presented here investigates the effects of pro-
teinmutation on drug bindingmode as characterized by the input
protein-ligand structure. How such mutations affect the overall
conformation of the target protein and/or drug-target complex
is not encompassed by our method. Extension of the approach
by considering the effect of residue mutation on global protein
conformation and by inclusion of structural models for highly ho-
mologous protein families would further expand the potential
impact and is the aim of our future studies. For example, FP mu-
tations that stabilize inactive protein conformations that are un-
likely to persist could be excluded, and mutations that further
stabilize an active protein conformation could be included.
Furthermore, drug-resistant mutations distant from the binding
site, including those which influence protein flexibility and
conformation, which are beyond the scope of our current
method, could also be evaluated.
This workflow includes three critical determinants of clinically
relevant drug-resistant mutations. Importantly, the workflow canCell Chemical Biology 25, 1–13, November 15, 2018 9
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example, Osprey parameters can be changed to include larger
backbone movements and/or to include multiple ligand ro-
tamers; furthermore, the number of prioritized mutants can
also be user-defined.
In conclusion, we have developed and validated a computa-
tional method to prospectively identify clinically relevant drug-
resistance mutations. We suggest that this approach can have
a significant impact on the design and development of targeted
therapies by proactively signposting drug resistance hotspots.
Prior knowledge of resistant mutants enables their timely detec-
tion in patients and the early development of effective treatment
options against the resistant tumor cell population.
SIGNIFICANCE
Althoughmolecularly targeted cancer therapies have shown
great success in the clinic, drug resistance has emerged as
the major challenge. Resistance mutations are commonly
identified and characterized during clinical evaluation, often
resulting in a reactive approach to tackling drug resistance.
We report a computational method to prospectively identify
drug resistancemutations during the design phase of poten-
tial therapeutics. This approach enables early signposting of
likely resistance hotspots and supports more focusedmoni-
toring of potential emergent resistant clones as well as the
timely development of alternative treatment options.
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METHOD DETAILS
Structure Selection and Preparation
When available, crystal structures of wild type protein were used. Formation of the Lys-Glu salt bridge was theminimum requirement
for kinase co-factor structures to be considered representative of an active conformation. Due to the paucity of high resolution
ATP-bound kinase protein structures, we employed ADP or ATP analogue complexes for all kinase structures representative of
endogenous co-factor binding. A list of employed PDB entries is provided in Table S7. All crystal structures were prepared using
the Preparation wizard (Sastry et al., 2013) in Maestro version 9.8.016 (Schro¨dinger Release, 2014). Bond orders were assigned
and hydrogens were added. Zero-order bonds to metals and disulphide bonds were created and selenomethionines were converted
to methionines. Missing side chains were added and all waters beyond 5 A˚ from heteroatoms, buffer compounds, and additional
chains were deleted. Ionization states were generated using Epik. H-bonds were assigned, water conformations were sampled
and structures minimized using default settings.
Residues within 12 A˚ of the ligand were selected using the selector tool in MOE 2015.1001 (Molecular Operating Environment
(MOE), 2017) and only selected residues were included in the input structure. As described in the Osprey documentation, the pro-
tonation state of histidines was defined in the pdb input file, all HETATM identifiers were replaced by ATOM, and chain information
was deleted.
Evaluation of Ligand Affinity
Osprey version 2.2beta (Chen et al., 2009; Gainza et al., 2013), using the Amber94 force field, was employed to evaluate the impact of
protein mutation on ligand binding. All non-peptide interaction partners were parameterized using Antechamber (AmberTools16
(Case et al., 2016)) as described in the Osprey documentation and only the selected crystal structure protein conformation was
used. Small molecule ligands were allowed to rotate and translate during the calculations.
Residues within 5 A˚ of the ligand were systematically mutated to all other possible amino acids, except if they were known to be
crucial for catalytic activity; namely the AspPheGly motif, catalytic Asp, and Lys-Glu salt bridge in kinases. All three His protonatione1 Cell Chemical Biology 25, 1–13.e1–e2, November 15, 2018
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Resistance Mutations in Cancer, Cell Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.013states were included; His was only considered as a resistant mutation when all protonation states were predicted to confer resis-
tance. Mutation to Pro is not supported by the Osprey package. In cases where ligands form specific water-mediated interactions
with the protein, the water molecules were included and defined as co-factor as suggested in the Osprey documentation. Only one
residue at a timewas allowed tomutate andWT rotamerswere included for all mutable residues. Residue positions were investigated
either individually or in pairs; this led to multiple WT K* scores per protein-ligand complex and the averageWT (avwt) score was used
henceforth. The ratio of the endogenous ligand to drug K* score (= K* ratio) was calculated (Frey et al., 2010; Reeve et al., 2015)
to evaluate the effect of each possible mutation on drug binding in relation to binding of the endogenous ligand. The log score of
the K* ratio was subsequently used. The range of WT scores (rangewt) across log-units was used to determine the variation range
of the method for each input structure which results from the quality of the input model. (Figure S1). A decrease in drug affinity
for a mutant compared to the WT protein has the potential to cause resistance, the activity cut-off for mutants was defined as a
log K* ratio higher than the average WT protein value plus the inherent variation range of the method as described in Equation 1:
cut  off = logðKratioavwtÞ+ rangewt (Equation 1)
Every mutation retrieving a value higher than the cut-off was considered as conferring resistance.
The avwt score was used to define K* score values for residue positions that were only investigated for either endogenous ligand or
drug. This was the case if a residue was within 5 A˚ of one but not the other.
Calculation of relP
The mutation type probabilities were taken from Alexandrov et al. (Alexandrov et al., 2013). The relevant signatures were extracted
based on the cancer type for which the drug was approved. In detail, the signatures operating in stomach cancer and lung adeno-
carcinoma were used to calculate relative probabilities for KIT/ALK and EGFR small molecule drugs, respectively. Colorectal cancer
signatures were employed for EGFR-antibody complexes. No signatures for CML (relevant for inhibitors of Abl) have been reported.
The original values of the signatures (xs) were normalized according to their total contribution to mutational load and the number of
samples in which the signature could be detected (cs) (Figure S2). The normalized signature probabilities of all relevant signatures
were added to give the overall probability for a specific base exchange in a particular cancer type (=SPM probability, pSPM) as
described in Equation 2:
pSPM=
Xsn
s1
cs  xs (Equation 2)
where:
s1 and sn are the first and n
th signature contributing to the mutational load in a particular cancer type.
The dataset of cancer-specific SPM probabilities is provided in Table S8 in the Supplemental Information.
To calculate the relP for a specific amino acid missense mutation, the coding sequence for each amino acid residue and their
5’ and 3’ neighbouring bases were extracted from the COSMIC database (Bamford et al., 2004). Signature-derived pSPMs
(as described above) were used to define the relP for a specific amino acid exchange according to Equation 3:
relP=
Xtn
t1
pSPM1  pSPM2 (Equation 3)
where:
t1 and tn are the first and n
th combination of base exchanges resulting in the desired protein residue change.
pSPM1 and pSPM2 are the overall probability for a specific base exchange 1 and 2 in a particular cancer type. DPMs have been
reported in cancer patients with similar frequency to insertions (Table S1) and were therefore included in the workflow. Please note,
that only pSPM1 is required if a protein residue mutation can be facilitated by a single base exchange (SPM), whereas both pSPM1
and pSPM2 are used for a DPM.
Whenever multiple different mutations led to the same amino acid exchange, the individual SPM probabilities were added. The
calculation of relP, exemplified on the EGFR T790M mutation in adenocarcinoma, is depicted in Figure S2.
QUANTIFICATION AND STATISTICAL ANALYSIS
Microsoft Excel was used to calculate the mean ± SEM across all 18 target-interaction partner case studies (=n) as reported in the
Discussion.Cell Chemical Biology 25, 1–13.e1–e2, November 15, 2018 e2
